Form 4: Rhythm Pharmaceuticals CFO Exercises Options and Sells Shares Under Pre-Arranged Plan

Rhythm Pharmaceuticals' Chief Financial Officer, Hunter C. Smith, exercised stock options and subsequently sold a portion of his common stock holdings on May 30, 2025, pursuant to a pre-arranged Rule 10b5-1 plan.

Summary

• On May 30, 2025, Hunter C. Smith, Chief Financial Officer of Rhythm Pharmaceuticals, Inc. (RYTM), acquired 23,400 shares of common stock by exercising stock options at an exercise price of $6.88 per share.
• Immediately following the option exercise, Mr. Smith disposed of a total of 23,400 shares of common stock through two separate sales transactions.
• The first sale involved 4,407 shares at a weighted average price of $60.9293 per share, with prices ranging from $60.33 to $61.32.
• The second sale involved 18,993 shares at a weighted average price of $61.5224 per share, with prices ranging from $61.33 to $61.62.
• These sales were conducted pursuant to a Rule 10b5-1 plan adopted by Mr. Smith on February 28, 2025.
• Following these transactions, Mr. Smith's direct beneficial ownership of common stock is 109,929 shares, and he also holds 77,194 stock options with an exercise price of $6.88, which are fully vested and expire on August 8, 2027.

Sentiment

Score: 5

Explanation: The filing reports routine insider transactions (option exercise and subsequent sale) under a pre-arranged plan, which is a neutral event regarding the company's operational performance or outlook. It reflects personal financial management by an executive.

Positives

• The exercise of stock options at a significantly lower price ($6.88) compared to the sale price (over $60) indicates a substantial personal gain for the Chief Financial Officer.
• The transactions were executed under a Rule 10b5-1 plan, which suggests pre-planned personal financial management rather than opportunistic trading based on non-public information.

Negatives

• The sale of 23,400 shares by a key executive, even under a 10b5-1 plan, represents a reduction in insider ownership, which some investors might interpret as a lack of confidence, although this is often for personal liquidity or diversification.

Future Outlook

This Form 4 filing is a report of insider transactions and does not contain information regarding the company's future outlook or guidance.

Industry Context

This filing is a standard disclosure of insider trading activity, common across all industries for publicly traded companies. It reflects individual executive financial planning rather than broader industry trends or competitive positioning.

Stakeholder Impact

• Shareholders: May observe a reduction in direct insider ownership, but the execution under a Rule 10b5-1 plan typically mitigates concerns about opportunistic selling, suggesting a pre-planned liquidity event for the executive.

Key Dates

Keywords

Rhythm Pharmaceuticals, RYTM, SEC Form 4, Insider Trading, Stock Options, Share Sale, Chief Financial Officer, Rule 10b5-1 Plan, Beneficial Ownership